Synagis® has been shown to reduce the rate of RSV-related hospitalizations in premature infants (≤35 weeks GA) by more than half 1 Significant reduction in RSV-related hospitalization rates with Synagis vs. placebo1-3

First Page		Document Content
Date: 2014-04-30 14:26:38 Mononegavirales Human respiratory syncytial virus Palivizumab Biology Health MedImmune Placebo AstraZeneca Medicine Viral diseases		Synagis® has been shown to reduce the rate of RSV-related hospitalizations in premature infants (≤35 weeks GA) by more than half 1 Significant reduction in RSV-related hospitalization rates with Synagis vs. placebo1-3 Add to Reading List Source URL: www.rsvfacts.com Download Document from Source Website File Size: 83,75 KB Share Document on Facebook

	Controlling Aedes aegypti and Aedes albopictus: Information for vector control programs Background yy Mosquito-borne viral diseases such as chikungunya, dengue, and Zika can cause similar symptoms, including fever with m DocID: 1uPwQ - View Document
	Possible Impacts of the Whitefly Q Biotype on Viral Diseases in Tomato Jane E. Polston Dept. Plant Pathology Univ. Of Florida DocID: 1toCV - View Document
	Clinical Infectious Diseases Advance Access published January 5, 2015 BRIEF REPORT Epidemiological and Viral Genomic Sequence Analysis of the 2014 Ebola DocID: 1rCcg - View Document
	Ebola fever - Oxford Reference DocID: 1rj6X - View Document
	SUPPLEMENT ARTICLE Contribution of Sec61a to the Life Cycle of Ebola Virus Ayaka Iwasa,1 Peter Halfmann,2 Takeshi Noda,1,3 Masaaki Oyama,4 Hiroko Kozuka-Hata,4 Shinji Watanabe,5 Masayuki Shimojima,5 Tokiko Watanabe,5 an DocID: 1riu1 - View Document